122 completed, 9 terminated, 9 unknown, 4 withdrawn. 51 Phase 4, 46 Phase 3, 25 Phase 1, 10 Phase 2, 7 Not applicable.
Follow Paliperidone Palmitate: new trials by email Literature Review of Paliperidone Palmitate trials Research Report on Paliperidone Palmitate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia Paliperidone Palmitate Injection (PP1M) - Schizophrenia | Phase 4 | Not yet recruiting | Jiangsu Province Nanjing Brain Hospital | 120 | 2025-10-01 | 2025-09-29 |
| Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder | Phase 4 | Active not recruiting | Dr. Stavroula Rakitzi | 84 | 2025-06-04 | 2026-05-01 |
| A Bioequivalence Study of PP3M in Patients With Schizophrenia Paliperidone Palmitate Injection (3M) - Schizophrenia | Not applicable | Recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 260 | 2024-10-09 | 2026-03-25 |
| Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia Paliperidone Palmitate Injection(PP1M), Paliperidone Palmitate Injection(PP1M)(Reference Group) - Schizophrenia | Not applicable | Completed | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 256 | 2023-12-18 | 2025-12-05 |
| Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis Aripiprazole, Paliperidone - Schizophrenia, Treatment-resistant Schizophrenia | Phase 4 | Unknown | Consorcio Centro de Investigación Biomédica en Red (CIBER) | 244 | 2023-11-01 | 2023-09-29 |
| An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Clozapine, Antipsychotics,Other (non-Clozapine) - Treatment-resistant Schizophrenia | Phase 4 | Terminated | Ohio State University | 5 | 2023-08-16 | 2026-02-25 |
| Risk of Breakthrough Symptoms With Long-Acting Injectable Medications Second Generation Long-Acting Injectable Antipsychotic Medications - Schizophrenia, Schizophrenia Relapse | Completed | Centre for Addiction and Mental Health | 51 | 2023-01-11 | 2026-04-14 | |
| "Extended" (Alternate Day) Antipsychotic Dosing Risperidone, Olanzapine, paliperidone - Schizophrenia and Related Disorders, Drug Administration Schedule | Phase 4 | Recruiting | Centre for Addiction and Mental Health | 120 | 2022-06-06 | 2026-04-13 |
| Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 89 | 2021-09-08 | 2024-03-19 |
| A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq. - Schizophrenia | Phase 4 | Completed | Janssen-Cilag International NV | 93 | 2021-07-22 | 2025-04-27 |
| Relative Bioavailability of LY03010 Compared to Listed Drug LY03010; paliperidone palmitate, INVEGA SUSTENNA - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 281 | 2021-01-13 | 2023-04-25 |
| Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients Paliperidone Palmitate - Schizophrenia Patients | Phase 1 | Completed | Luye Pharma Group Ltd. | 36 | 2020-01-22 | 2020-11-09 |
| The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk Paliperidone Palmitate - Schizophrenia | Unknown | Huazhong University of Science and Technology | 225 | 2019-08-18 | 2020-02-20 | |
| Substance Misuse To Psychosis for Stimulants Aripiprazole, Paliperidone, Treatment as Usual - Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 165 | 2019-06-01 | 2026-03-27 |
| A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe - Schizo Affective Disorder, Schizophrenia | Phase 1 | Completed | Luye Pharma Group Ltd. | 48 | 2018-12-12 | 2019-08-13 |
| A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly Paliperidone Palmitate 3-Month Formulation (PP3M) - Schizophrenia | Completed | Janssen-Cilag International NV | 225 | 2018-11-21 | 2025-04-27 | |
| A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq. - Schizophrenia | Phase 4 | Completed | Janssen Research & Development, LLC | 34 | 2018-10-18 | 2025-04-27 |
| A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal Oral Antipsychotics (OAPs), Paliperidone Palmitate 1-Month Formulation (PP1M) - Schizophrenia | Completed | Janssen-Cilag Farmaceutica Ltda. | 55 | 2018-08-07 | 2025-04-27 | |
| A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication ASP4345, placebo, risperidone - Schizophrenia | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 233 | 2018-07-13 | 2024-11-12 |
| A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment Paliperidone - Schizophrenia | Phase 1 / Phase 2 | Completed | Pharmathen S.A. | 70 | 2018-03-11 | 2019-07-19 |
Showing 20 of 148. Sign in to see all of them.
Schizophrenia (118) · Psychotic Disorders (29) · Mood Disorders (14) · Bipolar Disorder (10) · Depression (4) · Mental Disorders (4) · Mania (3) · Recurrence (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3) · Schizophrenia, Treatment-Resistant (3) · Affective Disorders, Psychotic (2) · Diabetes Mellitus (2) · Disease (2) · Social Adjustment (2) · Acute Disease (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (36) · Janssen Research & Development, LLC (10) · Janssen-Cilag International NV (7) · Janssen Korea, Ltd., Korea (5) · Janssen Pharmaceutical K.K. (5) · Janssen Scientific Affairs, LLC (4) · Johnson & Johnson Taiwan Ltd (4) · Luye Pharma Group Ltd. (4) · Ortho-McNeil Janssen Scientific Affairs, LLC (4) · Xian-Janssen Pharmaceutical Ltd. (4) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (2) · Calo Psychiatric Center (2) · Centre for Addiction and Mental Health (2) · Chonbuk National University Hospital (2) · Janssen Pharmaceutica (2)
United States (40) · South Korea (22) · China (16) · Germany (13) · Taiwan (13) · Belgium (12) · Ukraine (12) · Romania (11) · Russia (11) · Spain (11) · Bulgaria (10) · Malaysia (10) · France (9) · Greece (8) · India (8)
For-Wey Lung, MD, ScD (2) · Gang Wang, M.D. (2) · Rui Li, MD (2)
PMID 18466043, PMID 26934062, PMID 37756123, PMID 24754314, PMID 28640988, PMID 32606705, PMID 42752599, PMID 17224706, PMID 17466492, PMID 17690599, PMID 18165460, PMID 18559166, PMID 19481579, PMID 19959339, PMID 20216424, PMID 20389255, PMID 20473057, PMID 20492853, PMID 20565430, PMID 20947174, PMID 21092748, PMID 21155708, PMID 21481243, PMID 21569242, PMID 21696265, PMID 21777507, PMID 22377512, PMID 22516251, PMID 22809972, PMID 23446197, PMID 23842022, PMID 24113628, PMID 24144440, PMID 24491033, PMID 24559194, PMID 24581419, PMID 24846035, PMID 24870446, PMID 25375367, PMID 25444566, PMID 25562685, PMID 25938474, PMID 26232241, PMID 26306819, PMID 26403322, PMID 26742509, PMID 27136907, PMID 27247177, PMID 27333588, PMID 27574835
2008 (2), 2009 (1), 2015 (1), P50MH066286 (1), R01MH080270 (1), R01MH081107 (1), U01MH070007 (1), U01MH070008 (1), U01MH070009 (1), U01MH070010 (1), U01MH070011 (1), U01MH070012 (1), U01MH070016 (1), U01MH070017 (1), U01MH070023 (1)